Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
22 October 2013Website:
http://www.lipocine.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 37 min agoDividend
Analysts recommendations
Institutional Ownership
LPCN Latest News
SALT LAKE CITY , Oct. 23, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that it will present and meet with investors at the H.C. Wainwright 7th Annual NASH Investor Conference, taking place virtually October 24, 2023.
Lipocine (NASDAQ: LPCN ) stock is rising higher on Thursday after the company released positive results from a Phase 2 clinical trial. That trail covers the use of LPCN 1148 as a treatment for patients suffering from cirrhosis.
What type of business is Lipocine?
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.
What sector is Lipocine in?
Lipocine is in the Healthcare sector
What industry is Lipocine in?
Lipocine is in the Biotechnology industry
What country is Lipocine from?
Lipocine is headquartered in United States
When did Lipocine go public?
Lipocine initial public offering (IPO) was on 22 October 2013
What is Lipocine website?
https://www.lipocine.com
Is Lipocine in the S&P 500?
No, Lipocine is not included in the S&P 500 index
Is Lipocine in the NASDAQ 100?
No, Lipocine is not included in the NASDAQ 100 index
Is Lipocine in the Dow Jones?
No, Lipocine is not included in the Dow Jones index
When does Lipocine report earnings?
The next expected earnings date for Lipocine is 09 August 2024